Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS.

Blood reviews - 1 Jul 2023

Frumm Stacey M, Shimony Shai, Stone Richard M, DeAngelo Daniel J, Bewersdorf Jan Phillipp, Zeidan Amer M, Stahl Maximilian

Abstract excerpt

Approval of new agents to treat higher risk (HR) myelodysplastic syndrome (MDS) has stalled since the approval of DNA methyltransferase inhibitors (DNMTi). In addition, the options for patients with lower risk (LR) MDS who have high transfusion needs and do not harbor ring sideroblasts or 5q- syndrome are limited. Here, we review the current treatment landscape in MDS and identify areas of unmet need, such as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Drug Development

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Mutation

Share to Myelodysplastic Syndromes

Source

Identifiers

PMID: 36805300
DOI: 10.1016/j.blre.2023.101056

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS.PMID 36805300Read ↗

Therapy for lower-risk MDS.Semantic proximity Read ↗

Current and emerging strategies for management of myelodysplastic syndromes.Semantic proximity Read ↗

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.Semantic proximity Read ↗

Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?Semantic proximity Read ↗

Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?Semantic proximity Read ↗

[Novel therapies for MDS and future prospects].Semantic proximity Read ↗

Current therapeutic approaches for patients with myelodysplastic syndromes.Semantic proximity Read ↗

IL-1β–mediated inflammatory signaling drives ineffective erythropoiesis in early-stage myelodysplastic syndromesSemantic proximity Read ↗

Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.Semantic proximity Read ↗

Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".Semantic proximity Read ↗

Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.Semantic proximity Read ↗

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.